Use of adipose tissue-derived stromal stem cells in treating fistula
AssigneesTiGenix, S.A.U., Universidad Autonoma De Madrid
InventorsMaría Gema FERNÁNDEZ MIGUEL, Manuel Angel GONZALEZ DE LA PENA, Rosa Ana GARCIA CASTRO, Mariano GARCIA ARRANZ, Damian GARCIA-OLMO
Life of this patent
Estimating the term…
Abstract
Provided herein are novel methods and compositions utilizing adipose tissue-derived stromal stem cells for treating fistulae.
Claims16
1-35. (canceled)
A method of preparing a pharmaceutical composition, comprising thawing a cryopreserved composition and formulating the thawed composition with human serum albumin (HSA) and Dulbecco's Modified Eagle's Medium (DMEM) to produce the pharmaceutical composition, wherein the cryopreserved composition comprises an isolated cell population comprising adipose tissue-derived stromal stem cells, wherein the isolated cell population was ex vivo generated by culturing cells from adipose tissue for at least six days and passaging the cells from adipose tissue at least four times, wherein the concentration of the adipose tissue-derived stromal stem cells in the cryopreserved composition is at least about 5×106 cells/mL.
A method of preparing a pharmaceutical composition, comprising formulating an isolated cell population with HSA and DMEM to produce the pharmaceutical composition, wherein the isolated cell population comprises adipose tissue-derived stromal stem cells, wherein the isolated cell population was ex vivo generated by culturing cells from adipose tissue for at least six days and passaging the cells from adipose tissue at least four times, wherein the concentration of the adipose tissue-derived stromal stem cells in the pharmaceutical composition is at least about 5×106 cells/mL.
Dependencies are inferred from the claim text.